Vaccine Info

mRNA-1653 hMPV+PIV3 Vaccine

Description

mRNA-1653 is a combination vaccine that consists of two distinct mRNA sequences encoding the fusion (F) proteins of hMPV and PIV3 formulated in Moderna’s proprietary lipid nanoparticle (LNP) technology.

Indication

mRNA-1653 is designed to protect against human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3), two viruses that cause respiratory infections. 

Dosage

 

Clinical Trial NCT03392389:  Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

  • This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.  
Updated
August 23rd, 2019